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Abstract 
Asparagine-linked glycosylation is a common post-translational modification of proteins in 
eukaryotes. Mutations in the human ALG3 gene cause changed levels and altered glycan 
structures on mature glycoproteins, and are the cause of a severe Congenital Disorder of 
Glycosylation (CDG-Id). Diverse glycoproteins are also underglycosylated in Saccharomyces 
cerevisae alg3 mutants. Here we analysed site-specific glycosylation occupancy in this yeast 
model system using peptide-N-glycosidase F to label glycosylation sites with an asparagine-
aspartate conversion that creates a new endoproteinase AspN cleavage site, followed by 
proteolytic digestion, and detection of peptides and glycopeptides by LC-ESI-MS/MS. We 
used this analytical method to identify and measure site-specific glycosylation occupancy in 
alg3 mutant and wild type yeast strains. We found decreased site-specific N-glycosylation 
occupancy in the alg3 knock-out strain preferentially at Asn-Xaa-Ser sequences located in 
secondary structural elements, features previously associated with poor glycosylation 
efficiency. Furthermore, we identified 26 previously experimentally unverified glycosylation 
sites. Our results provide insights into the underlying mechanisms of disease in CDG-1d and 
our methodology will be useful in site-specific glycosylation analysis in many model systems 
and clinical applications. 
 
 
Introduction 
Protein N-glycosylation is a common and essential co- and post-translocational modification 
of membrane and secreted proteins that in eukaryotes is catalysed by the multiprotein 
complex enzyme oligosaccharyltransferase (OTase) 1. The oligosaccharide Glc3Man9GlcNAc2 
is assembled on the lipid carrier dolicholpyrophosphate and transferred en bloc by OTase 
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onto selected asparagines, primarily in N-glycosylation sequons (NX(S/T); X≠P) as nascent 
polypeptide is translocated into the endoplasmic reticulum (ER) 1, 2. Further extension and 
modification of the glycan structures on mature proteins occurs in the Golgi 3-5. N-glycans 
assist protein folding in the ER, and the specific glycan structures on mature glycoproteins 
modulate protein function in developmental programs, during immune responses, in cell-cell 
interactions and in many other cellular processes 6-8. 
 
A number of the genes that encode for enzymes in the N-glycosylation pathway have been 
shown to be involved in human health and disease 6, 9. Many studies have revealed that 
alterations in glycan expression are associated as causative or incidental factors in relatively 
rare Congenital Disorders of Glycosylation (CDG), widespread acquired diseases and cancer 
6, 7, 9-11. CDGs are conceptually divided into CDG-I, where the genetic defect is in the ER in 
the N-glycosylation pathway before addition of glycan to protein, and CDG-II, where the 
defect is in the Golgi. Thus, CDG-I results in inefficient glycosylation of asparagines, while 
CDG-II results in changes to the glycan structures on mature glycoproteins 6.  
 
Underglycosylation is the underlying cause of disease in CDG-I, resulting in an increase in 
misfolded glycoproteins and alterations in their functions through reduced glycosylation of 
particular asparagines. However, with over half of all proteins predicted to be glycosylated, 
the sequence and structural diversity of protein acceptor sites is extraordinarily large 12. It is 
currently not clear which particular subset of asparagines are underglycosylated in CDG-I. 
However, a study using targeted SRM-MS showed that transferrin isolated from the blood of 
CDG-I patients had lower glycosylation occupancy specifically at its second N-glycosylation 
site 13. Additionally, several familial mutations in the homologous OTase subunits MagT1 and 
Tusc3 have been linked to a form of CDG-I leading to non-syndromic mental retardation 14-16. 
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Studies using a manipulable yeast genetic system showed that the yeast homologues of 
these proteins are required for efficient site-specific N-glycosylation of selected asparagines 
17, 18. Other CDGs have also been extensively studied in yeast. Saccharomyces cerevisiae alg 
mutants (alg, asparagine-linked glycosylation) are defective in the biosynthesis of the 
dolichol-linked Glc3Man9GlcNAc2,19, 20 and the mutations in the human alg homologs causing 
different types of CDG can be functionally studied by heterologous expression in yeast 6. The 
ALG3 gene is highly conserved in eukaryotes, and its mutation also results in a similar 
phenotype in Arabidobsis thalina 21, 22.  Knock-out mutants of these ALG genes in S. 
cerevisiae are generally viable, and have also been used to characterize the pathway of N-
glycosylation in the ER 19.  
 
Glycosylation occupancy can be measured semi-quantitatively on many proteins using MS-
based methods 17, 18, 23-25. Traditionally in these approaches in yeast, Endo H is used as a 
deglycosylation agent followed by protease treatment and MS analysis to identify glycosylated 
and non-glycosylated peptides. Enrichment of glycoproteins rather than glycopeptides allows 
detection of both glycosylated and non-glycosylated versions of the same peptide. This allows 
direct relative quantification of site-specific glycosylation occupancy, although entails some 
reduction in the enrichment efficiency obtainable through glycopeptide enrichment 25. Endo H 
cleaves all N-glycans of wild type yeast, which are all high-mannose structures, and 
conveniently leaves previously glycosylated asparagines tagged with a single N-
acetylglucosamine (GlcNAc)17. Glycan release with Endo H therefore provides a clear 
distinction between the glycosylated and unglycosylated versions of the same peptide with a 
Δmass of 203.08 Da. However, in S. cerevisiae Δalg3 mutants the incomplete precursor 
glycan Man5GlcNAc2-PP-Dol accumulates and Endo H resistant oligosaccharides are 
transferred to proteins 26. 
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In this study we chose a yeast Δalg3 strain as a model system to develop an MS-based 
method that can measure the occupancy of specific glycosylation sites in different proteins in 
situations where Endo H cannot be used. 
 
Experimental procedures 
Yeast Strains 
Yeast strains used were BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and the Δalg3 
mutant derivative thereof (Open Biosystems). Cells were grown to mid log phase at 30˚C in 
YPD (2% Bacto peptone, 1% yeast extract, and 2% glucose). 
 
Cell Wall Protein Sample Preparation 
Triplicates of 50 ml of cells grown to mid log phase were harvested and lysed with agitation 
for 1 hr at 4˚C using glass beads (Sigma) in 50 mM Tris HCl, pH 7.5, 1 mM PMSF and 1 x 
Complete protease inhibitor cocktail (Roche). Based on previously reported methods 17, 27, 
covalently linked cell wall material was pelleted by centrifugation at 18000 rcf for 1 min and 
washed 4 times with ice-cold 50 mM Tris-HCl pH 7.5. The pellet was resuspended in 50 mM 
Tris-HCl pH 8.0, 2 % SDS, 7 M Urea and 2 M Thiourea. Cysteines were reduced and 
alkylated by addition of dithiothretiol to 10 mM and incubation at 30˚C with agitation for 30 
min, followed by addition of acrylamide to 50mM and further incubation with agitation at 30˚C 
for 1 hr. Non-covalently linked proteins were removed by washing the 18000 rcf pellet five 
times with 1 ml 50mM Tris-HCl, pH 8, 2 % SDS, 7 M urea and 2 M thiourea, followed by five 
washes with 2 % SDS. The pellet was resuspended in 100 µl 1% NP40 and 1x G7 buffer 
(New England Biolabs) and aliquoted into 50 µl followed by addition of 500 units of PNGase F 
(New England Biolabs) and incubated at 37˚C with agitation for 16 h. The negative control 
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was incubated in the same buffer without PNGase F enzyme. The cell wall proteins were 
pelleted at 18000 rcf and washed 5 times in 50 mM Tris-HCl pH 8.0. The final cell wall pellet, 
equivalent to 12.5 ml of cell culture, was resuspended in 50 mM NH4HCO3, and proteins were 
digested with either trypsin 4 µg/ml (Sigma) or AspN 1 µg/ml (Promega) at 37˚C for 16 h with 
agitation.  
 
Mass Spectrometry and data analysis 
Peptides were desalted using C18 ZipTips (Millipore) and analysed by LC-ESI-MS/MS using 
a Prominence nanoLC system (Shimadzu) and TripleTof 5600 mass spectrometer with a 
Nanospray III interface (AB SCIEX). Approximately 2 µg peptides were desalted on an Agilent 
C18 trap (300 Å pore size, 5 µm particle size, 0.3 mm i.d. x 5 mm) at a flow rate of 30 µl/min 
for 3 min, and then separated on a Vydac EVEREST reversed-phase C18 HPLC column (300 
Å pore size, 5 µm particle size, 150 µm i.d. x 150 mm) at a flow rate of 1 µl/min. Peptides 
were separated with a gradient of 10-60 % buffer B over 45 min, with buffer A (1 % 
acetonitrile and 0.1 % formic acid) and buffer B (80 % acetonitrile with 0.1 % formic acid). Gas 
and voltage setting were adjusted as required. An MS TOF scan from m/z of 350-1800 was 
performed for 0.5 s followed by information dependent acquisition of MS/MS with automated 
CE selection of the top 20 peptides from m/z of 40-1800 for 0.05 s per spectrum. Peptides 
were identified using ProteinPilot (AB SCIEX), searching the LudwigNR database 
(downloaded from http://apcf.edu.au as at 27 January 2012; 16,818,973 sequences; 
5,891,363,821 residues) with standard settings: Sample type, identification; Cysteine 
alkylation, acrylamide; Instrument, TripleTof 5600; Species, S. cerevisiae with common 
contaminants; ID focus, biological modifications; Enzyme, trypsin or AspN; Search effort, 
thorough ID. False discovery rate analysis using ProteinPilot was performed on all searches. 
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Peptides identified with greater than 99 % confidence and with a local false discovery rate of 
less than 1 % were included for further analysis, and MS/MS fragmentation spectra were 
manually inspected. Extracted ion chromatograms were obtained using PeakView 1.1. 
Relative quantification of site-specific glycosylation occupancy was determined for each 
deamidated (deglycosylated) / unmodified (non-glycosylated) tryptic peptide pair without 
considering variable response factors of the unmodified and deamidated peptides. 
Occupancy was defined as the ratio of the extracted ion intensities of the deamidated peptide 
ion to the sum of the intensities of the deamidated and unmodified peptide ions 17.  
 
 
Results 
Identification and relative quantification of N-glycosylation site occupancy in cell wall proteins 
from wild type and Δalg3 yeast cells using PNGase F treatment followed by trypsin digestion. 
We asked whether glycosylation occupancy in the yeast Δalg3 strain showed site-specific 
alterations. To efficiently detect multiple glycosylation sites, enrichment of glycoproteins is 
required 17, 28. Enrichment of yeast cell wall proteins ensures detection of both glycosylated 
and non-glycosylated forms of proteins since the covalent linkage of the proteins to the yeast 
polysaccharide cell wall matrix does not rely directly on N-glycans. Previous methods for 
analysis of site-specific N-glycosylation occupancy in yeast have used glycan release with 
Endo H 17, 18, 23, 24. However, the glycan structures on mature glycoproteins in the yeast Δalg3 
mutant are altered, with the mutant glycan structures engendering the glycoproteins resistant 
to deglycosylation with Endo H 29. We therefore deglycosylated cell wall enriched 
glycoproteins from Δalg3 and wild type yeast strains with the general deglycosylating enzyme 
PNGase F, leaving previously glycosylated asparagines “tagged” with a deamidation (m/z ~ 1 
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Da). Deglycosylated covalently attached cell wall proteins were digested with trypsin, 
detected by LC-ESI-MS/MS and identified with ProteinPilot (AB SCIEX). We identified 
peptides containing 19 NX(S/T) sequons as either previously glycosylated peptides modified 
with deamidation, or non-glycosylated unmodified peptides. This gave a total of 29 peptides 
(> 99 % confidence) from 12 different proteins (Table 1, Supporting Information). We 
measured the relative glycosylation occupancy 17 at these 19 sites by measurement of 
deamidated-peptide / peptide pairs (Table 2, and Fig. 1 A and C). We found 10 N-
glycosylation sites that showed decreased levels of glycosylation occupancy in Δalg3 
compared to wild type. Ecm33p_328 showed the most severe decrease in glycosylation 
occupancy at 37 % (Table 2 and Fig. 1 A-D). Some glycosylation sites showed only mild 
under-glycosylation, such as Crh1p_177 that showed 96 % occupancy in the Δalg3 mutant 
(Table 2). We found six sites that were completely (100 %) glycosylated in both Δalg3 and 
wild type cells, and three sites were found to be completely non-glycosylated in both wild type 
and mutant yeast cells (Table 2). Two glycosylation sites were mildly under-glycosylated in 
wild type cells, Ecm33p_328 (Table 2 and Fig. 1 A and B) and Pry3p_101, and were both 
found to be further under-glycosylated in the Δalg3 strain (Table 2). In summary, we found 16 
glycosylation sites that were occupied in wild type cells, 10 of which were under-glycosylated 
in the Δalg3 strain.  
 
Spontaneous deamidation of NG sequences has been reported to occur during standard 
proteomic sample preparation 30-32. It was therefore important to confirm that the deamidation 
events we detected were due to PNGase F catalysed glycan release, rather than 
spontaneous chemical deamidation of non-glycosylated asparagines. Two of the detected 
glycosylation sites, Crh2p_310 and Gas1p_40, have sequons with the sequence NGS/T 
  9 
(Table 1), and would therefore be prone to spontaneous deamidation. We did not detect any 
deamidated peptide corresponding to Crh2p_310 in negative control samples not 
deglycosylated with PNGase F. In the negative control of Δalg3 cells we did detect a weak 
MS peak corresponding to ions of deamidated Gas1p_40 peptide, indicating that some 
portion of the unglycosylated form of this peptide underwent spontaneous deamidation during 
sample preparation (data not shown). However, no such peak was detected in the wild type 
negative control, indicating that this site is completely glycosylated in wild type, and is partially 
under-glycosylated in Δalg3 cells. The intensity of the deamidated Gas1p_40 peptide in the 
negative control was very low and was neglected in calculation of relative glycosylation 
occupancy at this site, leading to a slight underestimation of the level of under-glycosylation at 
Gas1p_40 in the Δalg3 strain (Table 2).  No detectable spontaneous deamidation of 
asparagines in other sequons were detected in any of the negative controls.  
 
Identification of N-Glycosylation sites in yeast cell wall proteins with PNGase F treatment 
followed by AspN digestion.  
Deglycosylation with PNGase F and digestion with trypsin allowed detection and relative 
quantification of site occupancy in Δalg3 cells. However, the mass shift upon deamidation is 
~1Da, which in some cases can be difficult to differentiate from the normal isotopic distribution 
of non-deamidated peptides in the case that the deamidated and non-deamidated versions of 
that peptide are not separated by C18 LC prior to MS detection. This is in contrast to the 
ready differentiation of previously glycosylated asparagines tagged with a Δmass of 203.08 
Da in the case of Endo H glycan release. This ambiguity has the potential to make 
measurement of site-specific N-glycan occupancy difficult. To overcome these difficulties and 
to further identify specific N-glycosylation sites showing under-glycosylation in Δalg3 yeast 
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cells, we therefore treated the cell-wall glycoproteins with PNGase F followed by digestion 
with the protease AspN and detection with LC-ESI-MS/MS. Deamidation of a previously 
glycosylated asparagine converts the amino acid to an aspartic acid that will be recognized as 
a cleavage site for AspN. Consequently AspN will cleave at deamidated asparagines that 
were glycosylated prior to treatment with PNGase F. This will allow clear differentiation of 
previously glycosylated asparagines, in contrast to the difficulties of PNGase F/trypsin as 
described above. Using this approach we identified 49 peptides (> 99 % confidence) that had 
been cleaved at a deamidated asparagine in a sequon (glycosylated) or contained an 
unmodified sequon (non-glycosylated) (Table 3, Supporting Information). The 49 peptides 
represented 42 NX(S/T) sequons in 14 different proteins (Table 3). 37 of these sequons were 
identified as glycosylated. We found seven sequons that were present in unmodified peptides 
(Table 3). Three of these unmodified sequons (Ecm33p_328, Gas3p_350 and Crh2p_96) 
were only found in Δalg3 samples and were also detected as peptides cleaved at the 
corresponding deamidated asparagine in both wild type and Δalg3 cells, indicating partial 
glycosylation at these three sites in the Δalg3 mutant. Four sequons were identified 
exclusively as non-glycosylated. Two of these (Ecm33p_209 and Crh1p_177) were only 
detected from Δalg3 cells, indicating that these sites are under-glycosylated in the Δalg3 
mutant strain (Table 3). Crh1p_177 was also identified in tryptic peptides both as a 
(deamidated) glycopeptide and a non-modified peptide (Table 1), showing some under-
glycosylation at this site (Table 2). In total we identified five glycosylation sites that were 
under-glycosylated in the Δalg3 mutant strain using PNGase F followed by AspN treatment. In 
addition, we identified two sequons in non-modified peptides, Ccw14p_87 and Tos1p_417, 
present in both wild type and Δalg3 positive and negative controls (no PNGase F treatment), 
suggesting that these two sequons are not glycosylated in wild type or the Δalg3 mutant strain 
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(Table 3).  AspN cleavage due to spontaneous deamidation of an asparagine in an NGS 
sequon was detected at minor levels at Gas1p_40 in the Δalg3 negative control, indicating 
that a portion of this site that was not glycosylated in these cells underwent spontaneous 
chemical deamidation. Relative quantification of glycosylation site occupancy was not 
performed using AspN peptides due to the inability to directly compare the deamidated and 
unmodified forms of the same peptide. 
 
Characteristics of sequons that showed decreased glycosylation occupancy in Δalg3 cells. 
N-Glycosylation is a general co-translational modification affecting many glycosylation sites 
on many different proteins within the cell. Only  ~ 70 % of NX(S/T) sequons are glycosylated 
in proteins that are translocated into the ER 17, 18, 23, 24. However, the sequons that were 
normally glycosylated in wild type cells were not evenly affected in the Δalg3 mutant strain – 
some sites remained efficiently glycosylated while others showed severe under-glycosylation. 
We compared the characteristics of glycosylation sites that were underglycosylated and sites 
that showed no change in glycosylation occupancy in Δalg3 cells (Table 2 and 4). We found 
that sequons that were efficiently glycosylated in Δalg3 cells were more likely to be located in 
loops of folded proteins (not in secondary structural elements) and contain threonine in the +2 
position (Fig 2).   
 
Identification of novel N-glycosylation sites in yeast cell wall proteins. 
In S. cerevisae there are 196 N-glycosylation sequons that have been directly experimentally 
shown to be occupied (UniProt) 17, 33. The method we describe here used cell wall enriched 
proteins that contain a limited number of proteins compared to a recently described method 
using filter-aided-sample-preparation (FASP) from whole cell extracts enriched for 
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glycoproteins with ConA 33. Nonetheless, using our approach we found in total 54 different 
occupied glycosylation sites (Table 1 and 3), 26 of which have not been reported previously 
(Table 5), raising the total number of known occupied N-glycosylation sites in S. cerevisae to 
222.  
 
 
Discussion 
We developed an LC-MS based analytical method to identify N-glycosylation sites and 
successfully determined the relative glycosylation occupancy at 19 sites using the yeast Δalg3 
strain as a model. Independent of the yeast strain studied, deglycosylation with PNGase F 
followed by AspN digestion increased the number of glycosylation sites that could be detected 
in a complex protein sample at one time, when compared with trypsin digest. It appears that 
proteins with multiple N-glycosylation sites become more accessible to digest with AspN and 
MS analysis after treatment with PNGase F compared with Endo H. Of the 26 new sites we 
found in this study, 22 were identified using the combination of PNGase F and AspN. In total 
we could detect 54 different occupied glycosylation sites. The approach we describe here is 
therefore complementary to standard techniques, and increases the number of N-
glycosylation sites that can be detected at the same time on many different proteins. 
 
While most glycosylation sequons were efficiently glycosylated in wild type cells, the altered 
glycan structure in the Δalg3 strain reduces the general glycosylation activity of OTase, 
leading to underglycosylation 26, 29. However, glycosylation sites were not uniformly affected in 
Δalg3 cells, with the subset of sites with lower affinity for OTase most strongly affected. We 
found 13 specific glycosylation sites that were under-glycosylated in the Δalg3 strain 
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compared to wild type cells (Table 4). The features of these glycosylation sites suggest that 
they are the subset of normally modified sites that are more difficult for OTase to glycosylate. 
For instance, these under-glycosylated sites are enriched in serine at the +2 position (Fig 2A). 
NxS sequons are glycosylated ~40 times less efficiently than NxT sequons,34 because of 
specific recognition of threonine at the +2 position by the peptide acceptor binding site of 
OTase 35. Under-glycosylated sites in the Δalg3 strain were also likely to be present in 
secondary structural elements (helices or sheets), whereas efficiently glycosylated sites were 
more likely present in flexible loops (Fig 2B). Protein folding competes with glycosylation by 
OTase because the peptide acceptor binding site of OTase requires a flexible stretch of 
peptide for tight binding 35. As secondary structure forms early in protein folding, glycosylation 
sites in secondary structural elements will have reduced affinity to OTase. The subset of 
glycosylation sites both present in flexible loops and with threonine at the +2 position were 
efficiently glycosylated (Fig 2C), suggesting a combination of these factors influences peptide 
acceptor binding to OTase, and hence glycosylation efficiency.  
 
Incorporation of either of the homologous proteins Ost3p or Ost6p into OTase results in 
enzyme isoforms with different protein substrate specificities at the level of individual 
glycosylation sites 17. Six of the 13 sites that show under-glycosylation in Δalg3 cells have 
been shown to be under-glycosylated in yeast cells with double knockout of these 
homologous OTase subunits (Δost3/Δost6) 17. All six of these sites were shown to be rescued 
by overexpression of Ost3p, although two sites could be rescued by over-expressing of either 
Ost3p or Ost6p 17. Furthermore, one glycosylation site, Gas1p_253, was shown to require 
Ost6p for complete glycosylation occupancy 17. Interestingly, we found that glycosylation 
occupancy of Gas1p_253 was not affected in Δalg3 cells  (Table 2), which express both 
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Ost3p- and Ost6p-containing OTase isoforms. This emphasizes the importance of the protein 
substrate specificities of OTase isoforms in defining the characteristics of an efficiently 
glycosylated asparagine.  
 
Our results may be complicated by the ability of many proteins to fold correctly even without 
glycosylation at many sites, as long as a certain critical level of glycosylation is present. This 
will mean that if glycosylation is strictly required at a particular asparagine for correct protein 
folding, then that asparagine will appear to always be glycosylated, even though most of the 
nascent polypeptide that is not modified will be degraded by the quality control systems of the 
ER 2. In addition, glycosylation efficiency may depend on factors such as local folding of the 
target protein close to the sequon and the protein substrate specificities of the particular 
OTase isoforms present 17, 36. However, in combination this and previous studies have 
detected almost every sequon in both glycosylated and non-glycosylated forms, suggesting 
that these effects are relatively minor. Therefore, it is reasonable to imply that sites that are 
easier to glycosylate would be expected to show full occupancy and sites that are more 
difficult to glycosylate would be found under-glycosylated.  
 
 
Conclusion 
Mutations in the human ALG3 gene cause a rare form of CDG (CDG-Id) 37. Reduced OTase 
activity due to the altered structure of the lipid-linked glycan substrate in this disorder is likely 
to affect N-glycosylation occupancy in a site-specific manner, similar to the patterns we 
observe here in a S. cerevisiae model system. We predict that glycosylation sites in NxS 
sequons and those located in secondary structural elements will be the most likely to show 
reduced glycosylation in CDG-Id. Many different diseases and health conditions in addition to 
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the CDG spectrum are caused by or associated with defects in glycosylation and 
consequently decreased levels of N-glycosylation occupancy at many different glycosylation 
sites in many different proteins. In conjunction with appropriate glycoprotein or glycopeptide 
enrichment strategies, the method we describe here could potentially be further developed to 
study human N-glycosylation site occupancy using clinical tissue, serum or saliva protein 
samples, leading to discovery of new biomarkers for CDG and other disorders and improved 
diagnostics. 
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Tables 
Table 1. Peptides containing N-glycosylation sequons identified by mass spectrometry. 
Proteins covalently linked to the yeast polysaccharide cell wall were prepared, glycans were 
released by peptide-N-glycosidase F, and proteins were digested with trypsin, detected by 
LC-ESI-MS/MS, and identified by ProteinPilot. 
Protein 
name	   Peptide position	   Sequence	   Asn	   m/z	   z	   ΔMass	  
Gas1p	   35-47	   FFYSNNGSQFYIR	   40	   548.5878	   3	   -0.0001	  
Gas1p	   35-47	   FFYSNNGSQFYIR	   40	   548.2642	   3	   0.0132	  
Gas1p	   48-77	   GVAYQADTANETSGSTVNDPLANYE
SCSR	   57	   1031.453	   3	   0.0056	  
Gas1p	   48-77	   GVAYQADTANETSGSTVNDPLANYE
SCSR	   57	   1031.123	   3	   -0.0014	  
Gas1p	   91-105	   VYAINTTLDHSECMK	   95	   599.6099	   3	   -0.0042	  
Gas1p	   253-271	   NLSIPVFFSEYGCNEVTPR	   253	   1122.536	   2	   0.0008	  
Gas5p	   50-73	   GVDYQPGGSSNLTDPLADASVCDR	   60	   837.0438	   3	   0.0022	  
Gas5p	   50-73	   GVDYQPGGSSNLTDPLADASVCDR	   60	   836.7169	   3	   0.0055	  
Pst1p	   51-65	   CDTLVGNLTIGGGLK	   57	   766.9019	   2	   -0.0025	  
Pst1p	   51-65	   CDTLVGNLTIGGGLK	   57	   766.4099	   2	   -0.0023	  
Ecm33p	   318-335	   GGANFDSSSSNFSCNALK	   328	   939.4022	   2	   0.0002	  
Ecm33p	   318-335	   GGANFDSSSSNFSCNALK	   328	   938.909	   2	   -0.0023	  
Pry3p	   100-120	   YNYSNPGFSESTGHFTQVVWK	   101	   817.042	   3	   0.0019	  
Pry3p	   100-120	   YNYSNPGFSESTGHFTQVVWK	   101	   816.7147	   3	   0.0039	  
Yjl171cp	   219-240	   NSSSIGYYDLPAIWLLNDHIAR	   219	   840.4252	   3	   0.0044	  
  21 
Yjl171cp	   219-240	   NSSSIGYYDLPAIWLLNDHIAR	   219	   840.0991	   3	   0.0102	  
Plb2p	   47-60	   NASGLSTAETDWLK	   47	   747.3575	   2	   -0.0042	  
Plb2p	   47-60	   NASGLSTAETDWLK	   47	   746.8659	   2	   -0.0032	  
Plb2p	   185-200	   SIVNPGGSNLTYTIER	   193	   574.6266	   3	   -0.0051	  
Plb2p	   362-382	   YVNNLSQDDDDIAIYAANPFK	   365	   796.0468	   3	   0.0061	  
Plb2p	   491-509	   NLTDLEYIPPLVVYIPNTK	   491	   1102.099	   2	   0.0019	  
Gas3p	   268-288	   LNSTFEDAVIPLIFSEYGCNK	   269	   811.3958	   3	   0.0039	  
Gas3p	   268-288	   LNSTFEDAVIPLIFSEYGCNK	   269	   811.0667	   3	   0.0004	  
Crh1p	   175-186	   FHNYTLDWAMDK	   177	   770.8482	   2	   0.0002	  
Crh1p	   175-186	   FHNYTLDWAMDK	   177	   771.3389	   2	   -0.0023	  
Crh2p	   23-59	   ATFCNATQACPEDKPCCSQYGECGT
GQYCLNNCDVR	   28	   1098.453	   4	   0.0215	  
Crh2p	   310-326	   NGTSAYVYTSSSEFLAK	   310	   609.288	   3	   0.0003	  
Tos1p	   412-421	   AAVIFNSSDK	   417	   526.271	   2	   -0.0071	  
Yil169cp 508-532	   GEGVLAVDPTETNATPIPVVGYTGK	   520	   829.1041	   3	   0.0157	  
Deamidated asparagines are bold. Unglycosylated sequons are underlined. All methionines are 
oxidized and all cysteines are alkylated. All peptides listed were identified with > 99 % confidence. 
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Table 2. Site-specific N-glycosylation occupancy in Δalg3 yeast strain. The relative N-
glycosylation occupancy at a given site was determined from the abundance of deamidated-
modified and unmodified versions of the same sequon-containing peptide as measured by 
LC-ESI-MS.  
Strain 
Glycosylation site 
Wild type Δalg3 
Gas1p_95	   1.00±0.00*	   1.00±0.00	  
Gas1p_253	   1.00±0.00	   1.00±0.00	  
Plb2p_193	   1.00±0.00	   1.00±0.00	  
Plb2p_491	   1.00±0.00	   1.00±0.00	  
Crh2p_28	   1.00±0.00	   1.00±0.00	  
Crh2p_310	   1.00±0.00	   1.00±0.00	  
Gas5p_60	   1.00±0.00	   0.97±0.05	  
Crh1p_177	   1.00±0.00	   0.96±0.01	  
Gas1p_40	   1.00±0.00	   0.94±0.05	  
Gas3p_269	   1.00±0.00	   0.92±0.04	  
Pry3p_101	   0.96±0.02	   0.85±0.02	  
Pst1p_57	   1.00±0.00	   0.76±0.12	  
Plb2p_47	   1.00±0.00	   0.66±0.17	  
Gas1p_57	   1.00±0.00	   0.57±0.11	  
Yjl171cp_219	   1.00±0.00	   0.51±0.18	  
Ecm33_328	   0.99±0.01	   0.37±0.08	  
Plb2_365	   0.00±0.00	   0.00±0.00	  
Tos1p_417	   0.00±0.00	   0.00±0.00	  
  23 
Yil169cp_520	   0.00±0.00	   0.00±0.00	  *,	  Values	  are	  mean	  of	  biological	  triplicates.	  Error	  is	  SD.	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Table 3. Peptides containing N-glycosylation sequons identified by mass spectrometry. 
Proteins covalently linked to the yeast polysaccharide cell wall were prepared, glycans were 
released by peptide-N-glycosidase F, and proteins were digested with AspN, detected by LC-
ESI-MS/MS, and identified by ProteinPilot.	  
Protein 
name	   Peptide Position	   Peptide Sequence	   Asn	   m/z	   z	   ΔMass	  
Gas1p	   23-39	   D*DVPAIEVVGNKFFYSN.NGS	   40	   957.4678	   2	   0.0003	  
Gas1p	   40-53	   NGSQFYIRGVAYQA	   40	   525.5922	   3	   0.0021	  
Gas1p	   77-94	   DIPYLKKLNTNVIRVYAI.NTT	   95	   711.7537	   3	   0.0035	  
Gas5p	   150-165	   DNVLGFFAGNEVINSV.NTT	   166	   847.9219	   2	   -0.0020	  
Gas5p	   166-179	   NTTNTATYVKAVVR	   166	   769.9114	   2	   -0.0017	  
Gas5p	   319-343	   DFENLKNEYSKVSNPEGNGGYSTSN.
NYS	   344	   917.4109	   3	   0.0007	  
Ecm33p	   45-55	   DKISGCSTIVG.NLT	   56	   575.7883	   2	   -0.0080	  
Ecm33p	   82-91	   NSSSLSSFSA	   82	   494.2102	   2	   -0.0135	  
Ecm33p	   202-213	   DNLVWANNITLR#	   209	   714.8843	   2	   0.0020	  
Ecm33p	   214-226	   DVNSISFGSLQTV.NAS	   227	   683.8457	   2	   -0.0007	  
Ecm33p	   241-257	   NLTQLSKVGQSLSIVSN	   241	   894.9885	   2	   -0.0006	  
Ecm33p	   258-266	   DELSKAAFS.NLT	   267	   484.2396	   2	   -0.0012	  
Ecm33p	   279-286	   NNTQLKVI	   279	   465.7654	   2	   -0.0020	  
Ecm33p	   287-303	   DGFNKVQTVGGAIEVTG.NFS	   304	   846.4332	   2	   -0.0007	  
Ecm33p	   323-345	   DSSSSNFSCNALKKLQSNGAIQG#	   328	   809.7242	   3	   0.0011	  
Ecm33p	   328-345	   NFSCNALKKLQSNGAIQG	   328	   655.6658	   3	   -0.0031	  
Pry3p	   91-100	   DAWYGEISKY.NYS	   101	   616.2849	   2	   -0.0005	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Yjl171cp	   286-299	   DLGTGIQSYGYITR.NTT	   300	   772.392	   2	   0.0017	  
Ccw14p	   73-91	   DAAYSAFKSSCSEQNASLG	   87	   669.6309	   3	   0.0022	  
Plb1p	   81-91	   DTSLLSTLFGS.NSS	   92	   570.7927	   2	   -0.0001	  
Plb1p	   265-276	   DGRYPGTTVINL.NAT	   277	   653.3411	   2	   -0.0049	  
Plb1p	   492-512	   DLEYIPPLIVYIPNSRHSFNG.NQS	   513	   815.4273	   3	   0.0064	  
Plb2p	   83-93	   DTSLLSTLFSS.NSS	   94	   585.7971	   2	   -0.0019	  
Plb2p	   162-170	   NWTSVQEIV	   162	   538.7665	   2	   -0.0001	  
Plb2p	   493-514	   DLEYIPPLVVYIPNTKHSFNG.NQS	   515	   806.0919	   3	   0.0063	  
Plb2p	   567-579	   NATLPPECTKCFA	   567	   769.3527	   2	   -0.0045	  
Plb2p	   615-629	   DGIPITALLGSSTSG.NTT	   630	   694.8669	   2	   -0.0003	  
Gas3p	   201-211	   NRSIPVGYSAA	   201	   568.2903	   2	   -0.0009	  
Gas3p	   191-200	   DMKQYISKHA.NRS	   201	   610.8044	   2	   -0.0078	  
Gas3p	   339-349	   D*DFVNLESQLK.NVS	   350	   654.3276	   2	   0.0001	  
Gas3p	   350-363	   NVSLPTTKESEISS	   350	   746.8725	   2	   0.0000	  
Gas3p	   339-363	   D*DFVNLESQLKNVSLPTTKESEISS#	   350	   927.4709	   3	   0.0145	  
Gas3p	   370-384	   DNSAITNIYSGFGTN.NFT	   385	   787.36	   2	   0.0000	  
Gas3p	   414-421	   DYAVPTTF.NYT	   422	   457.219	   2	   0.0005	  
Crh1p	   117-129	   NGTGIVSSFYLQS	   117	   687.3319	   2	   -0.0017	  
Crh1p	   173-180	   DKFHNYTL#	   177	   519.2554	   2	   -0.0016	  
Crh1p	   192-200	   DGESVRVLS.NTS	   201	   481.2486	   2	   -0.0051	  
Crh2p	   82-95	   DYSSKLGNANTFLG.NVS	   96	   743.8612	   2	   -0.0021	  
Crh2p	   82-100	   DYSSKLGNANTFLGNVSEA#	   96	   993.9658	   2	   -0.0160	  
Crh2p	   175-189	   DLETAQTNFYWESVL.NYT	   190	   908.4202	   2	   -0.0105	  
Crh2p	   223-232	   DGVVGRTLYK.NET	   233	   554.3093	   2	   -0.0044	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Crh2p	   237-252	   NATTQKYQYPQTPSKV	   237	   927.9626	   2	   -0.0052	  
Crh2p	   253-260	   DISIWPGG.NST	   261	   422.7143	   2	   0.0013	  
Crh2p	   282-296	   DISNPGYYYAIVNEV.NIT	   297	   858.9086	   2	   -0.0016	  
Crh2p	   310-326	   NGTSAYVYTSSSEFLAK	   310	   913.4259	   2	   -0.0045	  
Tos1p	   222-235	   DWSRGSYFVPGSTS.NCT	   236	   773.3513	   2	   -0.0016	  
Tos1p	   407-419	   DGTLKAAVIFNSS	   417	   661.8506	   2	   -0.0011	  
Pir3p	   231-244	   NSTLSMSLSKGILT	   231	   726.8838	   2	   -0.0011	  
Pst1p	   215-227	   DVHSVSFANLQKI.NSS	   228	   729.3972	   2	   0.0124	  
Deamidated asparagines are bold. Unglycosylated sequons are underlined. *, missed cleavage. #, 
Peptides containing unglycosylated sequons identified in Δalg3 only. All methionines are oxidized 
and all cysteines are alkylated. All peptides listed were identified with > 99 % confidence. 
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Table 4. Summary of N-glycosylation sites that are underglycosylated in Δalg3 
Glycosylation site	   Phenotype	   Identified with	  
Gas1p_40	   mild	   Trypsin	  
Gas1p_57	   strong	   Trypsin	  
Gas5p_60	   mild	   Trypsin	  
Pst1p_57	   medium	   Trypsin	  
Ecm33_209	   n.a.	   AspN	  
Ecm33_328	   strong	   Trypsin/AspN	  
Pry3p_101	   medium	   Trypsin	  
Yjl171cp_219	   strong	   Trypsin	  
Plb2_47	   strong	   Trypsin	  
Gas3p_269	   mild	   Trypsin	  
Gas3p_350	   n.a.	   AspN	  
Crh1p_177	   mild	   Trypsin/AspN	  
Crh2p_96	   n.a.	   AspN	  
n.a. not applicable 
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Table 5. Novel N-glycosylation sites detected using PNGase F. 
Uniprot ID	   Protein name	   Occupied N-glycosylation sites	  
Q08193	   Gas5p	   Asn 166	  
P38248	   Ecm33p	   Asn 56, 82, 227, 241, 304	  
P47033	   Pry3p	   Asn 101	  
P46992	   Yjl171cp	   Asn 219, 300	  
P39105	   Plb1p	   Asn 92, 277	  
Q03674	   Plb2p	   Asn 47, 94, 162, 515, 567	  
Q03655	   Gas3p	   Asn 269, 385, 422	  
P53301	   Crh1p	   Asn 201	  
P32623	   Crh2p	   Asn 190, 237, 261, 297	  
Q03180	   Pir3p	   Asn 231	  
Q03180	   Pst1p	   Asn 57	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Figure legends  
 
Figure 1. LC-ESI-MS/MS identification and relative quantificatiotion of glycosylation 
occupancy at Asn328 of Ecm33p from wild type and Δalg3 cells. Extracted ion chromatograms 
of the [M+2H]2+ ions corresponding to deamidated peptide at an m/z of 939.40 (dashed line) 
and unmodified peptide at an m/z of 938.91 (solid line) from wild type (A) and (B) and Δalg3 
(C) and (D). The glycoprotein enriched cell wall proteins were treated with PNGase F followed 
by trypsin (A and C), or with trypsin (B and D). The ratio of the area under the deamidated 
peptide to the total of deamidated and unmodified peptide gave a relative occupancy of 0.98 
in wild type (A) and 0.37 in Δalg (C) in this single measurement. The scale of the intensity is 
the same in A and B. MS/MS spectra and ProteinPilot matched fragmentation of deamidated 
peptide (E) and unmodified peptide (F) are shown. 
 
Figure 2: Characteristics of glycosylation sites that are underglycosylated in Δalg3 cells. 
Proportion of glycosylation sites that are present in (A) loops, (B) NxT sequons or (C) NxT 
sequons in loops, that show no change in occupancy (black) or that are underglycosylated 
(white) in Δalg3 cells compared with wild type cells. * p<0.05, ** p<0.01, Fisher’s exact test. 
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